Drug Approval | July 17, 2025
SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
This marks the fourth acquisition by Corona Remedies from multinational corporations
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Subscribe To Our Newsletter & Stay Updated
